Cyramza 500 MG/50 ML vial 50ML
Ended Awarded
- Contract number
- SPE2DB25FDL53
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,790
Award facts
- Contract value 100% obligated
- $20,790.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order on September 4, 2025, by the Defense Logistics Agency (DLA) for Cyramza 500 mg/50 ml vials with a ceiling value of $20,790.12. This delivery order was issued without a set-aside designation and carries an ultimate completion date of September 25, 2025. The award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $499,999,999 through November 2026, which authorizes the issuance of firm fixed-price orders for comprehensive pharmaceutical products supporting military health facility supply needs worldwide.
Cyramza (ramucirumab) is an oncology therapeutic used in cancer treatment protocols, and this delivery order fulfills the DLA's medical supply requirements for Department of Defense healthcare facilities. DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal supply chain through consistent contract performance delivering branded and generic prescription drugs, biologics, and medical consumables to military healthcare systems. The company's positioning as a woman-owned small business has enabled it to compete effectively in federal procurement markets while maintaining a robust portfolio of pharmaceutical product deliveries to defense-related agencies.
Quick answers
Who was awarded contract SPE2DB25FDL53?
SPE2DB25FDL53 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 4, 2025.
How much is contract SPE2DB25FDL53 worth?
The government has obligated $20,790 on SPE2DB25FDL53.
Is contract SPE2DB25FDL53 an order under another contract?
Yes. SPE2DB25FDL53 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDL53 competed?
The extent of competition for SPE2DB25FDL53 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award